The blockbuster study IMpower150 (NCT02366143) showed that the combination of atezolizumab and bevacizumab conferred synergistic efficacy to patients with metastatic non-squamous NSCLC in terms of PFS and median OS, regardless of EGFR or ALK aberration or the expression of PD-L1 (99). This evidence concerns the gene EGFR and non-small cell lung carcinoma.